

Oncocount RGCC™

Results



Analysis on a patient test patient 1 suffering from Breast carcinoma stage II.



The sample that was sent to us for analysis was a sample of 20ml Blood that contains anti-coagulant, and packed with an ice pack.

Laboratory Process

Isolation of malignant cells using flow cytometry with which the circulating tumor cells are enumerated and immunophenotyped

The results during the isolation procedure are presented below

Table of markers

Significant CD45 positive cells (Hematologic origin cells)

CD34

Negative

CD45 negative cells (non Hematologic origin)

CD133

Positive (25% of all CTC)

CD44

Negative

Index of markers

CD45

Hematologic origin cell marker

CD133, CD44

Tumor stem cell marker

CD34

Hematological stem cell and blast cell marker, epithelioid sarcoma marker

Index of circulating cells number

If over limit: Advanced or progression of disease. If less than limit: Early disease or disease is responding to a treatment plan.

Breast Cancer

< 5 cells / 7.5 ml

Prostate Cancer

< 20 cells / ml

Sarcoma

< 15 cells / 6.5 ml

Colon Cancer

< 5 cells / ml

Lung Cancer

(Lc=0, r=0.99):< 10 cells / ml

All cancer types other than those listed above should be < 5 cells / ml

The final results after the isolation procedure are presented below

We notice that after isolation procedure there are remaining malignant cells.

The concentration of these cells was isolated 3.3 cells/7.5 ml, SD +/- 0.3cells.

Disclaimers

*This test will NOT DETECT cancers of the brain or other cancers that have been “encapsulated” by the body, not releasing circulating tumor or stem cells (CTC, CSC) into the blood stream or if any of these cells are dormant. We still recommend the use of biopsy, blood markers and/or various scans with this test when cancer is suspected or known to exist.No test is 100% accurate.

*The methodology has a sensitivity of 86,2% and specificity of 83,9%

Sincerely,

A handwritten signature in blue ink, appearing to read 'Ioannis Papatiriu', with a horizontal line extending to the right.

Ioannis Papatiriu MD., PhD Head of molecular medicine dpt. of R.G.C.C.-Research Genetic Cancer Centre International GmbH